Longeveron Inc. (LGVN)
After hours:
| Previous Close | 2.0900 |
| Open | 2.0800 |
| Bid | 2.0100 x 400 |
| Ask | 2.0800 x 900 |
| Day's Range | 1.9900 - 2.0814 |
| 52 Week Range | 0.7710 - 28.6000 |
| Volume | |
| Avg. Volume | 10,794,552 |
| Market Cap | 29.293M |
| Beta (5Y Monthly) | 0.42 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -8.8600 |
| Earnings Date | N/A |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 8.32 |
GlobeNewswireLongeveron to Present at the H.C. Wainwright 26th Annual Global Investment Conference
MIAMI, Aug. 26, 2024 (GLOBE NEWSWIRE) -- Longeveron Inc. (NASDAQ: LGVN), a clinical stage regenerative medicine biotechnology company developing cellular therapies for life-threatening and chronic aging-related conditions, today announced that it will participate in the H.C. Wainwright 26th Annual Global Investment Conference taking place September 9-11, 2024 in New York City. Details for the Company’s presentation: Date:Tuesday, September 10, 2024 Time:5:00 – 5:30 p.m. ET The webcast for this c
GlobeNewswireLongeveron® Announces Second Quarter 2024 Financial Results and Provides Business Update
Wa'el Hashad Wa'el Hashad, CEO, Longeveron Positive data from the Phase 2a clinical trial (CLEAR MIND ) evaluating Lomecel-B™ in Alzheimer’s disease presented in Featured Research Oral Presentation at Alzheimer’s Association International Conference® (AAIC)U.S. FDA granted Lomecel-B™ both Regenerative Medicine Advanced Therapy (RMAT) designation and Fast Track designation for the treatment of mild Alzheimer’s diseasePhase 2b clinical trial (ELPIS II) evaluating Lomecel-B™ in rare pediatric disea
- GlobeNewswire
Longeveron® to Report Second Quarter 2024 Financial Results and Host Conference Call on August 14, 2024
MIAMI, Aug. 05, 2024 (GLOBE NEWSWIRE) -- Longeveron Inc. (NASDAQ: LGVN), a clinical stage regenerative medicine biotechnology company developing cellular therapies for life-threatening and chronic aging-related conditions, today announced that it will report second quarter 2024 financial results and provide a business update on Wednesday, August 14, 2024 after the U.S. financial markets close. The Company will host a conference call and webcast the same day at 4:30 p.m. ET. Conference Call Detai
